Anti-PD1 ‘SHR-1210ʹ aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement
Author:
Affiliation:
1. UltraHuman Limited, Codebase, Edinburgh, UK
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/19420862.2018.1550321
Reference35 articles.
1. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
2. Development trends for human monoclonal antibody therapeutics
3. Antibodies to watch in 2018
4. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
5. A Modification of Jerne's Theory of Antibody Production using the Concept of Clonal Selection
Cited by 55 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics;mAbs;2024-08-24
2. Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab;Frontiers in Immunology;2024-04-05
3. An immune-related adverse event of Behcet’s-like syndrome following pembrolizumab treatment;BMC Pulmonary Medicine;2024-04-05
4. Reactive cutaneous capillary endothelial proliferations of the eyelids induced by camrelizumab: A case report;Biomedical Reports;2024-02-01
5. Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors;BMC Immunology;2024-01-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3